{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:39:33Z","timestamp":1793723973276,"version":"4.6.1"},"reference-count":72,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Eosinophilic myocarditis (EM) is a rare, life-threatening inflammatory cardiomyopathy driven by eosinophil cytotoxicity and extracellular trap formation. Interleukin-5 (IL-5) inhibition may disrupt this pathogenic cascade. We reviewed contemporary evidence on IL-5 blockade in EM and contextualized it with an illustrative case. Methods: We searched PubMed through May 2025 for reports of EM treated with mepolizumab or benralizumab. Inclusion criteria were consistent with prior cohorts: acute cardiac symptoms with biomarker elevation plus abnormalities on transthoracic echocardiography and\/or cardiac magnetic resonance imaging (CMR), along with documented IL-5-targeted therapy. We extracted clinical, imaging, biopsy, treatment-timing, and outcome data and included one institutional case. Results: Twenty-one episodes were analyzed (median age, 45 years; 10 men). Underlying conditions included eosinophilic granulomatosis with polyangiitis (10 cases; 48%), hypereosinophilic syndrome (5 cases; 24%), drug reaction with eosinophilia and systemic symptoms (DRESS, 3 cases; 14%), and eosinophilic asthma (3 cases; 14%). Treatments involved mepolizumab in 17 cases (81%) and benralizumab in 4 (19%); 4 patients received \u201cearly-start\u201d therapy within 14 days of EM diagnosis. Among the 11 episodes with reported left ventricular ejection fraction (LVEF) at baseline and follow-up, the median baseline LVEF was 40% (range, 30\u201362), with 10 of 11 (91%) &lt;50%. On follow-up, all 11 patients improved: 4 normalized (\u226550%) and 7 improved to 40\u201349%. CMR (n = 18) demonstrated late gadolinium enhancement in 14 cases (78%), edema in 9 (50%), and intracardiac thrombus in 4 (22%). Endomyocardial biopsy confirmed eosinophilic infiltration in 13 of 15 cases (87%). Outcomes included one death (fulminant DRESS), one recovery following veno-arterial extracorporeal membrane oxygenation, and one successful heart transplantation. Illustrative case: A 24-year-old man on a steroid taper received mepolizumab 300 mg on Day 4. His LVEF improved from 47% to 59% by Day 15, accompanied by biomarker decline and successful steroid tapering. Conclusions: Across published cases and our institutional experience, IL-5\u2013targeted therapy appears safe, steroid-sparing, and associated with rapid ventricular recovery, particularly when initiated early. Although limited, these findings support the need for prospective trials to define the optimal agent, dosing, timing, and integration with standard immunosuppression and anticoagulation.<\/jats:p>","DOI":"10.3390\/jcm14196829","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:30:03Z","timestamp":1758893403000},"page":"6829","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Eosinophilic Myocarditis Treated with IL-5 Blockade: An Integrated Case Report and Literature Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9781-258X","authenticated-orcid":false,"given":"Hidenori","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7154-3606","authenticated-orcid":false,"given":"Toru","family":"Awaya","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"},{"name":"Department of Cardiovascular Medicine, Toho University Ohashi Medical Center, 2-22-36, Ohashi Meguro-ku, Tokyo 153-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Nagamatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Satake","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Toba","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Toyama-Kousaka","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0922-8656","authenticated-orcid":false,"given":"Shinichiro","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miwa","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tajiri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Agemi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Yokohama Municipal Citizen\u2019s Hospital, 1-1, Mitsuzawa-Nishimachi, Kanagawa-ku, Yokohama 221-0855, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Shinkai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22, Higashi-Oi, Shinagawa-ku, Tokyo 140-8522, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Li, H., Dai, Z., Wang, B., and Huang, W. (2015). A case report of eosinophilic myocarditis and a review of the relevant literature. BMC Cardiovasc. Disord., 15.","DOI":"10.1186\/s12872-015-0003-7"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100118","DOI":"10.1016\/j.jtauto.2021.100118","article-title":"Diagnosis and treatment of eosinophilic myocarditis","volume":"4","author":"Zhong","year":"2021","journal-title":"J. Transl. Autoimmun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","article-title":"Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes","volume":"70","author":"Brambatti","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11886-024-02184-6","article-title":"Eosinophilic Myocarditis: A Concise Review","volume":"27","author":"Asada","year":"2025","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/art.41727","article-title":"Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis","volume":"73","author":"Fukuchi","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tomizawa, H., Yamada, Y., Arima, M., Miyabe, Y., Fukuchi, M., Hikichi, H., Melo, R.C.N., Yamada, T., and Ueki, S. (2022). Galectin-10 as a Potential Biomarker for Eosinophilic Diseases. Biomolecules, 12.","DOI":"10.3390\/biom12101385"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41419-020-2497-x","article-title":"In vivo evidence for extracellular DNA trap formation","volume":"11","author":"Yousefi","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.coi.2021.03.013","article-title":"Charcot-Leyden crystals and other protein crystals driving type 2 immunity and allergy","volume":"72","author":"Aegerter","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4049\/jimmunol.1800107","article-title":"Charcot-Leyden Crystals Activate the NLRP3 Inflammasome and Cause IL-1beta Inflammation in Human Macrophages","volume":"202","author":"Ataide","year":"2019","journal-title":"J. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Han, T., Tang, H., Lin, C., Shen, Y., Yan, D., Tang, X., and Guo, D. (2022). Extracellular traps and the role in thrombosis. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.951670"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2147\/JIR.S458692","article-title":"In-Depth Review of Loeffler Endocarditis: What Have We Learned?","volume":"17","author":"Su","year":"2024","journal-title":"J. Inflamm. Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kowtoniuk, R., Pinninti, M., Tyler, W., and Doddamani, S. (2018). DRESS syndrome-associated acute necrotizing eosinophilic myocarditis with giant cells. BMJ Case Rep., 2018.","DOI":"10.1136\/bcr-2018-226461"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Truong, K., Kelly, S., Bayly, A., and Smith, A. (2021). Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis. BMJ Case Rep., 14.","DOI":"10.1136\/bcr-2021-242240"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Watanabe, A., Nakamoto, Y., Aita, T., Naganuma, T., Takahashi, S., Kiko, Y., Nakagawa, H., and Hamaguchi, S. (2024). Fatal Myocarditis in Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Without Mortality-Related Risk Factors: A Case Report and Literature Review. Cureus, 16.","DOI":"10.7759\/cureus.63541"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Song, T., Jones, D.M., and Homsi, Y. (2017). Therapeutic effect of anti-IL-5 on eosinophilic myocarditis with large pericardial effusion. BMJ Case Rep., 2017.","DOI":"10.1136\/bcr-2016-218992"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Huynh, R., Sy, R.W., Wong, S.J., and Wong, C.C.Y. (2022). A unique case report of relapsing eosinophilic myocarditis causing atrial myopathy and persistent sinus arrest. Eur. Heart J. Case Rep., 6.","DOI":"10.1093\/ehjcr\/ytac047"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/mrcr\/rxab022","article-title":"Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis","volume":"6","author":"Higashitani","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.46497\/ArchRheumatol.2023.9823","article-title":"Mepolizumab therapy in a pediatric patient with eosinophilic granulomatosis with polyangiitis associated with refractory myocarditis","volume":"38","author":"Ulu","year":"2023","journal-title":"Arch. Rheumatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"159","DOI":"10.46497\/ArchRheumatol.2023.9559","article-title":"Mepolizumab therapy improves endomyocarditis in seropositive eosinophilic granulomatosis with polyangiitis","volume":"38","author":"Wang","year":"2023","journal-title":"Arch. Rheumatol."},{"key":"ref_21","first-page":"863","article-title":"Eosinophilic granulomatosis with polyangiitis-related myocarditis during mepolizumab therapy reveals a Th1\/Th17-mediated vasculitic response","volume":"40","author":"Bello","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Rao, K., Arustamyan, M., Walling, A., Christodoulidis, G., Ashwath, M., Hagedorn, J., and Priya, S. (2023). Utility of cardiac magnetic resonance imaging in diagnosing eosinophilic myocarditis in a patient recently recovered from COVID-19: A grand round case report. Eur. Heart J. Case Rep., 7.","DOI":"10.1093\/ehjcr\/ytad090"},{"key":"ref_23","first-page":"45","article-title":"Eosinophilic Granulomatosis with Polyangiitis in an 8-year-old Girl Manifesting as Hypereosinophilic Syndrome with Myocarditis, Stroke, and Subsequent Orbital Involvement","volume":"30","author":"Panina","year":"2023","journal-title":"Acta Med. Litu."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102267","DOI":"10.1016\/j.jaccas.2024.102267","article-title":"Interleukin-5 Antagonist Monoclonal Antibody Therapy Improves Symptoms and Reduces Steroid Dependence in Eosinophilic Myocarditis Patients","volume":"29","author":"Trovato","year":"2024","journal-title":"JACC Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Brick, C., Leet, A., Tay, H., Kaye, D.M., and Taylor, A.J. (2024). Fulminant eosinophilic myocarditis and refractory ventricular arrhythmias requiring mechanical circulatory support: A case report. Eur. Heart J. Case Rep., 8.","DOI":"10.1093\/ehjcr\/ytae409"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sharma, S., Desai, S., Leoni, J., Paghdar, S., Ruiz, J., and Goswami, R. (2024). Case report: Eosinophilic myocarditis in hypereosinophilic syndrome: A journey to heart transplantation. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1418665"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.alit.2020.03.001","article-title":"Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis","volume":"69","author":"Colantuono","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_28","first-page":"834","article-title":"Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis","volume":"40","author":"Belfeki","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","first-page":"18","article-title":"Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis: A Meta-Analysis of 62 Case Reports","volume":"15","author":"Pakbaz","year":"2020","journal-title":"J. Tehran Heart Cent."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11886-025-02258-z","article-title":"Cardiac Involvement in Eosinophilic Granulomatosis with Polyangiitis","volume":"27","author":"Srikantharajah","year":"2025","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_31","first-page":"703","article-title":"A case of cardiomyopathy due to allergic bronchopulmonary aspergillosis","volume":"39","author":"Matsuda","year":"1991","journal-title":"Kokyu Junkan."},{"key":"ref_32","first-page":"100","article-title":"Rapid effect of benralizumab in fulminant eosinophilic myocarditis in the setting of uncontrolled eosinophilic asthma","volume":"28","author":"Goyack","year":"2023","journal-title":"J. Cardiol. Cases"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/ggi.14329","article-title":"Successful treatment of an elderly patient with severe eosinophilic asthma and eosinophilic myocarditis using benralizumab","volume":"22","author":"Kodaka","year":"2022","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Tartaglia, F., Messina, M.R., Rizzo, S., Heffler, E., and Panico, C. (2025). Anti-interleukin-5 efficacy in an inclisiran-triggered eosinophilic myocarditis: A case report. Eur. Heart J. Case Rep., 9.","DOI":"10.1093\/ehjcr\/ytaf127"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107729","DOI":"10.4330\/wjc.v17.i6.107729","article-title":"Eosinophilic myocarditis due to parasitic infection: A case-based minireview","volume":"17","author":"Luong","year":"2025","journal-title":"World J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e614","DOI":"10.1161\/CIRCULATIONAHA.107.692574","article-title":"Images in cardiovascular medicine. Eosinophilic heart disease in acute myeloproliferative disorder","volume":"115","author":"Reuss","year":"2007","journal-title":"Circulation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1007\/s00392-021-01885-0","article-title":"Patients with acute myocarditis and preserved systolic left ventricular function: Comparison of global and regional longitudinal strain imaging by echocardiography with quantification of late gadolinium enhancement by CMR","volume":"110","author":"Meindl","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2024.10.080","article-title":"2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"85","author":"Writing","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10554-020-02097-9","article-title":"Use of the new Lake Louise Criteria improves CMR detection of atypical forms of acute myocarditis","volume":"37","author":"Cundari","year":"2021","journal-title":"Int. J. Cardiovasc. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Luetkens, J.A., Faron, A., Isaak, A., Dabir, D., Kuetting, D., Feisst, A., Schmeel, F.C., Sprinkart, A.M., and Thomas, D. (2019). Comparison of Original and 2018 Lake Louise Criteria for Diagnosis of Acute Myocarditis: Results of a Validation Cohort. Radiol. Cardiothorac. Imaging, 1.","DOI":"10.1148\/ryct.2019190010"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/ehjci\/jeaa346","article-title":"Eosinophilic heart disease: Diagnostic and prognostic assessment by cardiac magnetic resonance","volume":"22","author":"Antonopoulos","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1253\/circj.CJ-22-0696","article-title":"JCS 2023 Guideline on the Diagnosis and Treatment of Myocarditis","volume":"87","author":"Nagai","year":"2023","journal-title":"Circ. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11886-022-01680-x","article-title":"State-of-the-Art of Endomyocardial Biopsy on Acute Myocarditis and Chronic Inflammatory Cardiomyopathy","volume":"24","author":"Ammirati","year":"2022","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.hjc.2024.03.004","article-title":"Endomyocardial biopsy in clinical practice: The diagnostic yield and insights from a 5-year single-center experience","volume":"84","author":"Karameh","year":"2025","journal-title":"Hellenic J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Martens, P., Cooper, L.T., and Tang, W.H.W. (2023). Diagnostic Approach for Suspected Acute Myocarditis: Considerations for Standardization and Broadening Clinical Spectrum. J. Am. Heart Assoc., 12.","DOI":"10.1161\/JAHA.123.031454"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Shiomi, M., Watanabe, R., Ishihara, R., Tanaka, S., Nakazawa, T., and Hashimoto, M. (2025). Comparative Insights on IL-5 Targeting with Mepolizumab and Benralizumab: Enhancing EGPA Treatment Strategies. Biomolecules, 15.","DOI":"10.3390\/biom15040544"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/rheumatology\/keae085","article-title":"Cardiac involvement in eosinophilic granulomatosis with polyangiitis: Acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy","volume":"64","author":"Liu","year":"2025","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Polte, C.L., Bobbio, E., Bollano, E., Bergh, N., Polte, C., Himmelman, J., Lagerstrand, K.M., and Gao, S.A. (2022). Cardiovascular Magnetic Resonance in Myocarditis. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020399"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/annrheumdis-2021-221794","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis","volume":"81","author":"Grayson","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bogacka, J., Pawlik, K., Ciapala, K., Ciechanowska, A., and Mika, J. (2022). CC Chemokine Receptor 4 (CCR4) as a Possible New Target for Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415638"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: Interpretation of exhaled nitric oxide levels (FeNO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Roufosse, F.E., and Johansson, M.W. (2018). Editorial: Pathogenic Advances and Therapeutic Perspectives for Eosinophilic Inflammation. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00243"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1161\/CIRCULATIONAHA.121.058869","article-title":"Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation","volume":"146","author":"Kanaoka","year":"2022","journal-title":"Circulation"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood.2020005161","article-title":"Glucocorticoid-induced eosinopenia results from CXCR4-dependent bone marrow migration","volume":"136","author":"Hong","year":"2020","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/j.seminhematol.2012.01.006","article-title":"Evaluation and differential diagnosis of marked, persistent eosinophilia","volume":"49","author":"Mejia","year":"2012","journal-title":"Semin. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.resinv.2025.04.018","article-title":"Eosinophilic granulomatosis with polyangiitis: Current status and future perspectives","volume":"63","author":"Kamide","year":"2025","journal-title":"Respir. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1111\/all.16267","article-title":"Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma","volume":"79","author":"Fricker","year":"2024","journal-title":"Allergy"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.5414\/CP202446","article-title":"Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab","volume":"53","author":"Pouliquen","year":"2015","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jacbts.2020.05.005","article-title":"Eosinophil Deficiency Promotes Aberrant Repair and Adverse Remodeling Following Acute Myocardial Infarction","volume":"5","author":"Toor","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/gutjnl-2024-332033","article-title":"Novel IL-4\/HB-EGF-dependent crosstalk between eosinophils and macrophages controls liver regeneration after ischaemia and reperfusion injury","volume":"73","author":"Yang","year":"2024","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Merkel, P.A., Nair, P.K., Khalidi, N., Terrier, B., Hellmich, B., Bourdin, A., Jayne, D.R.W., Jackson, D.J., Roufosse, F., and Pagnoux, C. (2025). Two-year efficacy and safety of anti-interleukin-5\/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann. Rheum. Dis., online ahead of print.","DOI":"10.1016\/j.ard.2025.06.2131"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of Patients at Risk for and with Left Ventricular Thrombus: A Scientific Statement from the American Heart Association","volume":"146","author":"Levine","year":"2022","journal-title":"Circulation"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tan, B.E., Baqai, F., Padilla, F., Nimri, N., Cheung, J.W., Kottam, A., and Medina, H.M. (2025). Cardiac CT Versus Transesophageal Echocardiography Following Left Atrial Appendage Closure: A Systematic Review and Meta-Analysis. Circ. Cardiovasc. Imaging, 18.","DOI":"10.1161\/CIRCIMAGING.125.018151"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1172\/JCI116382","article-title":"Eosinophil cationic granule proteins impair thrombomodulin function. A potential mechanism for thromboembolism in hypereosinophilic heart disease","volume":"91","author":"Slungaard","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019000518","article-title":"Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps","volume":"134","author":"Marx","year":"2019","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Al-Maimoony, T., Al-Matari, K., Al-Habeet, A., Aljaber, N.N., Al-Marwala, M., and Al-Hashmi, S. (2025). Efficacy and safety of off-label direct oral anticoagulants vs. warfarin for left ventricular thrombus: An inverse probability of treatment weighting analysis. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1465866"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"De Luca, G., Cavalli, G., Campochiaro, C., Tresoldi, M., and Dagna, L. (2018). Myocarditis: An Interleukin-1-Mediated Disease?. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01335"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.alit.2023.09.001","article-title":"Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review","volume":"73","author":"Kamide","year":"2024","journal-title":"Allergol. Int."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6829\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:14:15Z","timestamp":1759032855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/19\/6829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":72,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["jcm14196829"],"URL":"https:\/\/doi.org\/10.3390\/jcm14196829","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}